Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Net Asset Value(s)

NET ASSET VALUE(S) MITON UK MICROCAP TRUST PLC  Miton UK MicroCap Trust plc 11 March 2024 Miton UK Microcap Trust plcIt is announced that at the close of business on 08 March 2024, the unauditedNet Asset Value per share of Miton UK Microcap Trust plc is:With the portfolio valued on a fair value basis:Including current period revenue to 08 March 2024                                             53.71p per ordinaryshareExcluding current period revenue                53.62p per ordinary share

Insider trading in subscription option TO1 - CEO Jonas Jönmark increases his stake in AcuCort AB

During the ongoing exercise period for subscription option TO1, AcuCort's CEO Jonas Jönmark has purchased 250,000 subscription options with the intention to convert them into shares during the TO period.AcuCort announces that CEO Jonas Jönmark has purchased 250,000 subscription options on Spotlight Stock Market for a total amount of 3,750 SEK, corresponding to an average price of 0.015 SEK per subscription option TO1. "Through the acquisition of subscription options, I have the opportunity to strengthen my ownership position in AcuCort ahead of the company's launch of the oral film

Publication in Journal of Neurosurgery Demonstrates Distinct Advantages of CLS´s Core Technology in Neurosurgical MR-guided Laser Ablation

Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS) today announces that a publication with the title “Preclinical assessment of a non-cooled MR thermometry-based neurosurgical laser therapy system” has been published in the well renowned Journal of Neurosurgery1The research presented was conducted by CLS and our partner ClearPoint Neuro, Inc., with neurosurgeon Dr. John Rolston, MD, PhD leading the study as Principal Investigator. An animal model was used to demonstrate the safety, accuracy, and efficacy of the neuro laser therapy system including MR thermometry software developed

Teleste reaches industry-first commercial deliveries of 1.8 GHz smart amplifiers in North America

TURKU, FINLAND – 11 March 2024 – Teleste has reached an industry-first customer approvals and field deployments of DOCSIS 4.0 compliant 1.8 GHz ICON amplifiers in the North American market. The volume manufacturing of these smart amplifiers utilizes Teleste’s own automated factory, with capacity ramp-up corresponding with volume demands from multiple customers. Teleste has received orders from four North American Cable operators, which can now start their network upgrades. These 1.8 GHz Smart Amplifiers will bring major benefits to Cable operators’ broadband services, including maximum line

OncoZenge Explores Strategic Options for BupiZenge™ in China

STOCKHOLM, SWEDEN – March 11, 2024 – OncoZenge AB (publ), a pharmaceutical company dedicated to the development of innovative solutions for oral pain relief, today announces that Eurosin Capital AB has been retained as advisors to explore strategic options for the introduction of BupiZenge™ in China.”The Chinese market represents a significant opportunity for BupiZenge. More than 4 million people are diagnosed with cancer in China every year. With the typically high prevalence of oral mucositis during cancer treatments there is a clear need for safe and effective, local, non-opioid pain

Kesko Corporation to host an investor event on 4 June 2024

Kesko will be hosting an investor afternoon on Tuesday, 4 June 2024, in order to provide an update on the company’s strategy, businesses and drivers for growth and profitability. The event will include presentations by the President and CEO Jorma Rauhala and other members of Group Management Board.   Kesko welcomes institutional investors, analysts and media representatives in person at its K-Kampus headquarters in Kalasatama, Helsinki (street address Työpajankatu 12).  All interested parties can follow the event via webcast in real time or as a recording. The event will be held in

Changes to Voi e-scooter operations during Cheltenham Festival

A man on a Voi e-scooter. CREDIT: Voi. Rental e-scooter company, Voi, is advising riders to plan their journeys in Cheltenham between 12 and 15 March as there will be changes due to the Cheltenham Festival. E-scooters are a sustainable and convenient way to access the racecourse, helping to reduce traffic and congestion during the popular Festival - but riders are reminded that drink-drive laws also apply to e-scooters. A new temporary parking area will be available inside Gate 1 at the racecourse and nearby parking bays at New Barn Lane and Cleevelands Drive will be

Brain+ announces that 58% of its warrants of series TO 3 are covered by early commitments

COMPANY ANNOUNCEMENT · Members of management and board members/observers have committed to exercise all their TO 3 warrants and provide additional guarantee commitments, covering 6% of the issue   · The company’s largest shareholders have so far provided firm commitments to exercise warrants and provide guarantees for a total of 52% of the issue · As earlier announced, the exercise price for the warrants of series TO 3 is DKK 0.11 and the exercise period runs from 11 March 2024 to 22 March 2024 · If all warrants are exercised/guaranteed, it will add DKK 3.14 million and three (3)

Fiskars Corporation’s directed share issue without consideration based on the Performance Share Plan

Fiskars CorporationStock Exchange ReleaseMarch 11, 2024 at 1.50 p.m. EET Fiskars Corporation’s directed share issue without consideration based on the Performance Share Plan The Board of Directors of Fiskars Corporation has decided on a directed share issue without consideration based on Fiskars Group’s Performance Share Plan in order to pay the share rewards for the plan period 2021–2023. In the share issue, 73,381 treasury shares are issued without consideration to the key personnel participating in the plan period 2021–2023, in accordance with the terms and conditions of the

Elkem focuses on core business, exits Vianode

Oslo, 11 March 2024 Elkem has decided to exit its financial investment in the advanced battery materials company Vianode. This is in line with the previously announced comprehensive programme for earnings improvements and capex reductions in Elkem, and a focus on Elkem’s core business. Going forward, Vianode will continue to be backed by global aluminium and renewable energy company Hydro and Altor Fund V, a fund managed by Altor Fund Manager. Through the highly skilled employees who have joined Vianode from Elkem since its founding in 2021, Vianode will continue to benefit from

AMSC ASA: Mandatory notification of trade

11 March 2024 - Peter D. Knudsen, board member of AMSC ASA ("AMSC" or the "Company"), has today acquired 4,000 shares in AMSC through the company Vilja AS. The price per share was NOK 24.4522, which implies a total consideration of NOK 97,808.80. Following the transaction, Vilja AS holds a total of 34,000 shares in AMSC, constituting approximately 0.047% of the Company's shares and votes. Please see attached primary insider notification form pursuant to the requirements of the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to

BioStock: BioInvent’s CEO comments on the study success in China

BioInvent’s partner in China, CASI Pharmaceuticals, has announced preliminary encouraging efficacy data for BioInvent’s lead drug candidate BI-1206 in combination with rituximab in cancer patients with non-Hodgkin’s lymphoma. BioStock reached out to BioInvent’s CEO Martin Welschof, who expects that 2024 will be a break-out year for the company, with multiple data readouts expected during the second half of the year.Read the full interview with Martin Welschof at biostock.se: https://www.biostock.se/en/2024/03/bioinvents-ceo-comments-on-the-study-success-in-china/ This is a press

Volvo Group signs agreement with Westport for joint venture to reduce CO2 emissions from long haul transport

The Volvo Group has signed an agreement according to the previously announced Letter of Intent with Westport Fuel Systems Inc to establish a joint venture to accelerate the commercialization and global adoption of Westport’s High Pressure Direct Injection (HPDI[TM]) fuel system technology for long-haul and off-road applications.The closing of the joint venture is subject to certain closing conditions, including regulatory and government approvals. It is anticipated that the joint venture will become operational following the formal closing which is expected in the second quarter of 2024.

AbbVie’s Produodopa® (foslevodopa-foscarbidopa) Accepted by Scottish Medicines Consortium as Treatment Option for Advanced Levodopa-Responsive Parkinson’s Disease

For Medical and Trade media. · Foslevodopa-foscarbidopa will soon be available for eligible patients with advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia in Scotland, providing an additional option when currently available combinations of treatments have not given satisfactory results[1] · Following the recommendation by the National Institute for Health and Care Excellence (NICE) in November 2023, this means foslevodopa-foscarbidopa will soon be available for use within the NHS across the UK[2] · The advice from the

Notice of Annual General Meeting in Sleep Cycle AB (publ)

The shareholders of Sleep Cycle AB (publ) (“Sleep Cycle”), reg. no. 556614-7368, are hereby invited to attend the Annual General Meeting (the “AGM”) to be held on 11 April 2024 at 09:30 CEST at Jacy’z hotel, floor 24, Drakegatan 10, 412 50 Gothenburg, Sweden. Admission and registration for the AGM will begin at 09:00 CEST.The Board of Directors has resolved, in accordance with the provisions of Sleep Cycle’s Articles of Association, that shareholders may also exercise their voting rights in advance by so-called postal voting. Right to participate and notification A) Attending the

Sivers Semiconductors announces an expanded loan facility of SEK 50 million

With this financing, the Company has secured funding for continued growthKista, Sweden // Mar. 11, 2024 // Sivers Semiconductors AB (STO: SIVE), (the "Company"), a leading supplier of integrated chips and modules for the most advanced communications and sensor solutions, has, according to previous communication in connection with the 2023 fourth-quarter report, agreed to entered into a loan agreement with Formue Nord and partners extending the previous SEK 75 million facility. The new SEK 50 million loan facility includes a SEK 35 million convertible loan at a fixed conversion rate of 4.86

Gaming Innovation Group - Mandatory notification of trade

Mikael Riese Harstad, board member and primary insider of Gaming Innovation Group Inc. (GiG), has today transferred 477,733 shares in GiG without consideration to his wife Helena Riese Harstad. This transaction will not change the number of shares held by Harstad and close associates, and after this transaction, Harstad and close associates owns 1,342,136 shares in GiG. For further information, contact: Tore Formo, Group CFO, tore@gig.com +47 916 68 678 This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Spinomenal Enhances 888 Collaboration with Italian Expansion

Spinomenal, the leading iGaming content provider, has amplified its Italian iGaming presence thanks to a new content partnership with 888 Italy. Spinomenal’s titles are being integrated via Pariplay’s aggregation platform, Fusion.Spinomenal made its debut in the Italian market in the summer and it has become an important region for the business. Players using 888 Italy will be able to enjoy a wide selection of games, including the hugely popular Majestic King, Book of Demi Gods 2, Egyptian Rebirth and many others.Italy joins the list of already established markets, including UK, Romania,

ColdZyme® certified under the new EU medical device regulation (MDR)

Enzymatica’s mouth spray ColdZyme® has received CE-certification under the new and more demanding European Union medical device regulation (MDR). This important milestone validates the company’s scientific data and extends product claims throughout the EU. The certification is a key pillar for expansion in several markets and is expected to have long-term positive effects on Enzymatica’s growth. Eurofins, a European approved notified body for medical devices, has certified the ColdZyme® product line MDR (class III) according to the European Union medical device regulation. MDR replaces

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BR0WHY71 Issuer Name ACUITY RM GROUP PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Jonathan Mark Swann City of registered office (if applicable) rickmansworth Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification

Inside information: Outokumpu downgrades its guidance for Q1 2024 – adjusted EBITDA expected to be at a similar or lower level compared to Q4 2023 due to the political strike in Finland

Outokumpu OyjInside informationMarch 11, 2024 at 12.15 pm EETInside information: Outokumpu downgrades its guidance for Q1 2024 – adjusted EBITDA expected to be at a similar or lower level compared to Q4 2023 due to the political strike in Finland Outokumpu downgrades its guidance for the first quarter of 2024 due to the political strike in Finland. The political strike is aimed against the Finnish government and is not related to Outokumpu’s labor relations. Majority of Outokumpu’s stainless steel and ferrochrome operations as well as Tornio port in Finland will be shut down for

There are no items matching the current filter
There are no more items matching the current filter
Back to top